
AstraZeneca’s Imfinzi (durvalumab) Receives NMPA’s Approval for Unresectable Stage III Non-Small Cell Lung Cancer
Shots: The approval is based on P-III PACIFIC study assessing Imfinzi vs PBO in 713 ‘all-comer’ patients (regardless of PD-L1 status) with unresectable,
[Read More...]